Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00342602 · ClinicalTrials.gov registry record
Genetics of Progressive Multifocal Leukoencephalopathy and Acquired Immunodeficiency Syndrome
A clinical trial, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- 450
- Enrollment target
NCT00342602: Completed study, sponsored by National Cancer Institute (NCI).
NCT00342602 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 450 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00342602 has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- 450 participants
- Enrollment target
Study Summary
This study will identify genetic factors associated with the development of progressive multifocal leukoencephalopathy (PML) in patients with acquired immunodeficiency syndrome (AIDS). PML is a life-threatening infection of the brain that affects about 5 percent of untreated patients with AIDS. Its symptoms include mental deterioration, vision loss, speech disturbances, ataxia (inability to coordinate movements), paralysis, and coma. PML is caused by a polyomavirus called the JC virus. It is estimated that up to 80 percent of the human population has been exposed to the JC virus, but the disease is very rare. The virus only becomes active in people who have compromised immune systems, such as those undergoing immune suppressive chemotherapy for cancer and those with damaged immune systems due to HIV. Patients who have participated in the Multicenter AIDS Cohort Study may be eligible for this study, as well as healthy normal volunteers who will serve as controls. The study will review clinical information from patients and analyze genetic factors from both patients and control subjects to investigate genes associated with AIDS and JC virus infection.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 450 participants |
| Start Date | 2005-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00342602
The ClinicalTrials.gov registry entry for NCT00342602 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 450 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00342602 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00342602 about?
NCT00342602 is a clinical study titled "Genetics of Progressive Multifocal Leukoencephalopathy and Acquired Immunodeficiency Syndrome". This study will identify genetic factors associated with the development of progressive multifocal leukoencephalopathy (PML) in patients with acquired immunodeficiency syndrome (AIDS). PML is a life-threatening infection of the brain that affects about 5 percent of untreated patients with AIDS. Its ...
What is the current status of trial NCT00342602?
This trial is currently completed. The enrollment target is 450 participants. The study started on 2005-08.
Who is sponsoring clinical trial NCT00342602?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.